newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Full Year 2024 Financial Results

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line